Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists.

LBVS of 12480 in-house compounds, followed by HTRF assay, resulted in one nonsteroidal compound (11) with antagonistic activity against FXR (69.01 ± 11.75 μM). On the basis of 11, 26 new derivatives (12a-z) were designed and synthesized accordingly. Five derivatives (12f-g, 12p, 12u, and 12y) showed better antagonistic activities against FXR than compound 11. Remarkably, the most potent derivative, 12u (8.96 ± 3.62 μM), showed antagonistic capability approximately 10 times and 8-fold higher than that of the control (GS) and the starting compound 11, respectively. 12u was further confirmed to have high binding affinity with FXRαLBD, FXR specificity over six other nuclear receptors, and potent antagonistic activity against FXR in two cell testing platforms. 12u strongly suppressed the regulating effects of CDCA on FXR target genes. The therapeutic potential of 12u was identified by lowering the contents of triglyceride and cholesterol in human hepatoma HepG2 cells and in the cholesterol-fed C57BL/6 mices.

[1]  Woody Sherman,et al.  Rapid Shape-Based Ligand Alignment and Virtual Screening Method Based on Atom/Feature-Pair Similarities and Volume Overlap Scoring , 2011, J. Chem. Inf. Model..

[2]  S. Fiorucci,et al.  Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. , 2009, Trends in pharmacological sciences.

[3]  M. Makishima,et al.  Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist. , 2007, Bioorganic & medicinal chemistry.

[4]  Jasmine Chen,et al.  Identification of Gene-selective Modulators of the Bile Acid Receptor FXR* , 2003, The Journal of Biological Chemistry.

[5]  D. Mangelsdorf,et al.  A Natural Product That Lowers Cholesterol As an Antagonist Ligand for FXR , 2002, Science.

[6]  S. Fiorucci,et al.  Farnesoid X receptor: from structure to potential clinical applications. , 2005, Journal of medicinal chemistry.

[7]  F. Baldelli,et al.  Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA. , 2011, Mini reviews in medicinal chemistry.

[8]  D. Moore,et al.  Nuclear Receptor-Dependent Bile Acid Signaling Is Required for Normal Liver Regeneration , 2006, Science.

[9]  Hualiang Jiang,et al.  Microwave-Assisted One-Pot Synthesis of Pyrazolone Derivatives under Solvent-Free Conditions , 2010, Molecules.

[10]  D. Moore,et al.  Stigmasterol, a Soy Lipid–Derived Phytosterol, Is an Antagonist of the Bile Acid Nuclear Receptor FXR , 2007, Pediatric Research.

[11]  B. Staels,et al.  FXR: a promising target for the metabolic syndrome? , 2007, Trends in pharmacological sciences.

[12]  E. Distrutti,et al.  Targeting farnesoid X receptor for liver and metabolic disorders. , 2007, Trends in molecular medicine.

[13]  S. Wright,et al.  Lithocholic Acid Decreases Expression of Bile Salt Export Pump through Farnesoid X Receptor Antagonist Activity* , 2002, The Journal of Biological Chemistry.

[14]  Hualiang Jiang,et al.  Danthron Functions as a Retinoic X Receptor Antagonist by Stabilizing Tetramers of the Receptor* , 2010, The Journal of Biological Chemistry.

[15]  T. Warner,et al.  Expression and activation of the farnesoid X receptor in the vasculature. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  D. Moore,et al.  FXR: a metabolic regulator and cell protector , 2008, Cell Research.

[17]  G. Bifulco,et al.  Discovery That Theonellasterol a Marine Sponge Sterol Is a Highly Selective FXR Antagonist That Protects against Liver Injury in Cholestasis , 2012, PloS one.

[18]  M. Makishima,et al.  Human Bile Salt Export Pump Promoter Is Transactivated by the Farnesoid X Receptor/Bile Acid Receptor* , 2001, The Journal of Biological Chemistry.

[19]  F. Baldelli,et al.  Farnesoid X receptor agonists in biliary tract disease , 2009, Current opinion in gastroenterology.

[20]  Differential Modulation of Farnesoid X Receptor Signaling Pathway by the Thiazolidinediones , 2009, Journal of Pharmacology and Experimental Therapeutics.

[21]  M. Makishima,et al.  The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. , 2001, Gastroenterology.

[22]  J. Lehmann,et al.  Bile acids: natural ligands for an orphan nuclear receptor. , 1999, Science.

[23]  K. Mitropoulos,et al.  Cholesterol 7 alpha-hydroxylase. , 1977, Journal of lipid research.

[24]  D. Rader,et al.  Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. , 2003, JAMA.

[25]  S. Fiorucci,et al.  Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment. , 2010, Current medicinal chemistry.

[26]  A. Moschetta,et al.  Nuclear bile acid receptor FXR protects against intestinal tumorigenesis. , 2008, Cancer research.

[27]  S. Nam,et al.  Farnesoid X-activated receptor antagonists from a marine sponge Spongia sp. , 2006, Bioorganic & medicinal chemistry letters.

[28]  Shawn P Williams,et al.  Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064. , 2008, Bioorganic & medicinal chemistry letters.

[29]  J. Chiang,et al.  Farnesoid X Receptor Responds to Bile Acids and Represses Cholesterol 7α-Hydroxylase Gene (CYP7A1) Transcription* , 2000, The Journal of Biological Chemistry.

[30]  G. B. Wisely,et al.  Conformationally constrained farnesoid X receptor (FXR) agonists: alternative replacements of the stilbene. , 2011, Bioorganic & medicinal chemistry letters.

[31]  M. Makishima,et al.  Identification of a nuclear receptor for bile acids. , 1999, Science.

[32]  J. Chiang,et al.  Farnesoid X Receptor Responds to Bile Acids and Represses Cholesterol 7 a-Hydroxylase Gene ( CYP 7 A 1 ) Transcription * , 2000 .

[33]  Yun Yen,et al.  Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. , 2007, Cancer research.

[34]  F. Baldelli,et al.  Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. , 2010, Progress in lipid research.

[35]  X. Shen,et al.  Structural and thermodynamic behavior of eukaryotic initiation factor 4E in supramolecular formation with 4E-binding protein 1 and mRNA cap analogue, studied by spectroscopic methods. , 2001, Chemical & pharmaceutical bulletin.

[36]  Giuseppe Bifulco,et al.  Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of farnesoid-X-receptor. , 2011, Journal of medicinal chemistry.